Silence Therapeutics plc (OTCMKTS:SLNCF) Stock Short Interest Report for October

Silence Therapeutics plc (OTCMKTS:SLNCF) was the recipient of a significant decline in short interest in October. As of October 15th, there was short interest totaling 136 shares, a decline of 94.2% from the September 30th total of 2,350 shares. Based on an average trading volume of 473 shares, the short-interest ratio is currently 0.3 days.

Silence Therapeutics Price Performance

Shares of Silence Therapeutics stock remained flat at $6.37 during trading hours on Monday. Silence Therapeutics has a 52-week low of $1.06 and a 52-week high of $6.38. The stock’s fifty day moving average is $4.42 and its two-hundred day moving average is $2.49.

About Silence Therapeutics

Silence Therapeutics plc is a biotechnology company focused on developing medicines that selectively silence disease-associated genes. The company uses RNA interference (RNAi), a biological process that reduces the production of specific proteins, to create potential treatments for cardiovascular, hematologic and other serious diseases.

Silence’s proprietary mRNAi GOLD platform is designed to deliver small interfering RNA (siRNA) medicines to the liver using GalNAc conjugation. Its pipeline has included zerlasiran (formerly SLN360), an investigational therapy intended to reduce production of lipoprotein(a), a genetically determined cardiovascular risk factor, and divesiran (formerly SLN124), an investigational treatment designed to regulate iron biology through suppression of the TMPRSS6 gene.